Rosalind Advisors’s Regentis Biomaterials RGNT Stock Holding History

Rosalind Advisors’s Portfolio RGNT Stock Details RGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$768K	Hold	251,510	–	–	0.31%	35
2025 Q4	$1.7M	Buy	+251,510	New	+$1.73M	0.6%	27

Other funds holding RGNT

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rosalind Advisors's RGNT Position: Q1 2026 in Review

Rosalind Advisors held its Regentis Biomaterials (RGNT) position steady in Q1 2026 at 251,510 shares worth $768K. The position accounts for 0.31% of the portfolio, ranked #35.

Rosalind Advisors first reported a position in RGNT in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.7M in Q4 2025. 3 funds tracked by Wall St. Rank hold RGNT as of Q1 2026.

Rosalind Advisors held 251,510 shares of Regentis Biomaterials worth $768K as of Q1 2026.
Rosalind Advisors left its Regentis Biomaterials share count unchanged in Q1 2026.
Regentis Biomaterials made up 0.31% of Rosalind Advisors's portfolio in Q1 2026, its #35 holding.
Rosalind Advisors first reported a position in Regentis Biomaterials in Q4 2025 and has held it in 2 quarters since.
Rosalind Advisors's Regentis Biomaterials position peaked at $1.7M in Q4 2025.
3 funds tracked by Wall St. Rank held Regentis Biomaterials as of Q1 2026.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.